Comparison · NCT03905512-c2c08ddf
SEL-212 vs KRYSTEXXA: Number of Participants With Serum Uric Acid (SUA) Reduction of < 6 mg/dL for at Least 80% of the Time
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. SEL-212 vs KRYSTEXXA: Number of Participants With Serum Uric Acid (SUA) Reduction of < 6 mg/dL for at Least 80% of the Time. Trial comparisons, record NCT03905512-c2c08ddf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03905512-c2c08ddf
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.53 | 0.424 | 0.634 | wilson | |
| Risk in group 2 | 0.46 | 0.359 | 0.564 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0704 | -0.0785 | 0.215 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.15 | 0.85 | 1.56 | log | |
| Odds ratio, group 1 over group 2 | 1.33 | 0.725 | 2.42 | log | |
| Number needed to treat, for one more participant with the outcome on SEL-212 than on KRYSTEXXA | 14.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | SEL-212 | Participants received SEL-212 via IV infusion every 28 days for up to 6 months | 44 | 83 | OG000 |
| Group 2 | KRYSTEXXA | Participants received KRYSTEXXA® according to the manufacturer's prescribing information every 14 days for up to 6 months | 40 | 87 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Serum Uric Acid (SUA) Reduction of < 6 mg/dL for at Least 80% of the Time
- Description
- The average of the data collected during Month 3 and Month 6 was reported.
- Time frame
- Up to Month 6
- Population
- ITT set included all randomized participants.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy
- NCT number
- NCT03905512
- Phases
- PHASE2
- Conditions
- Chronic Gout
- Interventions
- SEL-212, KRYSTEXXA®
- Lead sponsor
- Selecta Biosciences, Inc.
- Results first posted
- 2023-10-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03905512?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03905512-c2c08ddf